Re:Cognition Health achieves global quality standard for clinical research


Cognitive healthcare provider’s network of eight clinical trial sites achieves GCSA accredited status in seven key operational areas

Re:Cognition Health, the HSMA cognitive healthcare provider, has undergone a rigorous evidence-based assessment of its clinical research operations. Provided by Global Clinical Site Accreditation (GCSA), which provides an independent report on the quality, efficiency and effectiveness of current operational processes, the resulting accreditation offers reassurance to sponsors, contract research organisations, staff and patients that trial sites have been independently assessed against robust quality standards.

Re:Cognition Health has eight centres in the UK and USA, where it carries out international trials of disease-modifying and symptomatic drugs for Alzheimer’s disease and other neurological conditions. This network achieved the GCSA quality standard in all seven of the categories that are covered by the assessment: workforce quality accreditation; patient engagement; feasibility; study start-up & initiation; study management & closedown; R&D business strategy; and governance

“We take what we do very seriously because of the impact our trials can have on our patients and their families,” said Vicky Eyre, Re:Cognition Health’s clinical operations director. “We wanted to ensure we were providing the best quality service, while also developing our team. Through the GCSA accreditation process, we have been able to demonstrate best practices and processes.”

Jacqueline Johnson North, co-founder of GCSA, added: “The Re:Cognition Health staff were extremely enthusiastic and responsive to the GCSA process, demonstrating the deep-rooted commitment within the organisation to ensure they are working to the highest industry standards,” explained “The team were honest and open which enabled us to get a true picture of the clinical trials operational processes and the challenges involved, showing there is an incredibly positive attitude overall within the company to perform the trials to the best of everyone’s capabilities.”